Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer

Editorial

Benjamin Solomon et al. J Clin Oncol. 2012.

. 2012 Jan 10;30(2):119-21.

doi: 10.1200/JCO.2011.37.8638. Epub 2011 Oct 24.

No abstract available

Comment on

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Wells SA Jr, et al. J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24. J Clin Oncol. 2012. PMID: 22025146 Free PMC article. Clinical Trial.
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.
Houvras Y. Houvras Y. J Clin Oncol. 2012 Jan 10;30(2):200-2. doi: 10.1200/JCO.2011.38.7639. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162569 No abstract available.